Zimbabwe has declined a substantial American healthcare agreement valued at $367m (£272m) spanning five years over Washington's demand for sensitive data.
This move was revealed following a internal memorandum from December was disclosed, which showed President Emmerson Mnangagwa felt the arrangement was "skewed".
An official spokesman later stated that the US was requesting genetic material for research and commercial gain while refused to share the benefits from any future treatments.
"We are forced to start the difficult and regrettable process of winding down our health assistance in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the United States had provided more than $1.9bn for health programmes to Zimbabwe over the last two decades.
A physicians' group in Zimbabwe has appealed for more negotiations to secure a agreement acceptable to both sides so the country's critical HIV programme can proceed.
Wider Background
This development comes after a similar case in neighbouring Kenya, where a court halted a related deal with the US following legal challenges were filed about the safety of citizens' medical information.
Since resuming the presidency last year, US President Donald Trump has drastically cut foreign aid and closed the US Agency for International Development (USAID).
USAID had overseen aid for the American government, but Trump claimed its spending was "wasteful" and his government was seeking direct bilateral deals to enhance openness and responsibility.
Based on statements, Sixteen nations in Africa have so far agreed to these new agreements, constituting over $18.3bn of fresh investment.
Specifics of the Rejected Agreement
The funds for Zimbabwe would have supported "tackling HIV/Aids, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"We believe this cooperation could have provided extraordinary advantages for Zimbabwean communities, especially the 1.2 million men, women and children presently receiving HIV treatment through US-supported initiatives," the Ambassador added.
However, government spokesperson Nick Mangwana argued the proposed deal was "unequal".
"Zimbabwe was being asked to share its biological resources and data for a long time, without any equivalent assurance of access to any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that could result from that provided information," his statement read.
"In essence, our nation would provide the raw materials for scientific discovery without any certainty that the end products would be available to our citizens if a new disease outbreak arise."
Sovereignty and International Frameworks
He also noted that the American exit from the global health body and its pursuit of one-on-one deals were undermining frameworks already set up through the global organization.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing framework created to manage future pandemics.
"This system is intended to ensure that when a country contributes its information, the benefits – such as medicines and cures – are distributed fairly, not commercialised exclusively by those with the funds to create them."
Zimbabwe's reservations over the US deal "are not meant as opposition to America," Mangwana stressed.
"We are open to continued dialogue with our American counterparts on how future collaboration could be arranged in a manner that honours the sovereignty and interests of each country."
Health Experts Reaction
A leading public health body expressed it acknowledged the official position, but suggested that negotiations should continue since a large portion of the country's HIV programmes were funded by international support.
"In cases where specific concerns arise, including those relating to information security or implementation frameworks, these can frequently be resolved through detailed discussion and mutually agreed protections," the group added.
The situation emphasises the complex debate between accepting crucial international aid and protecting a country's data in an increasingly data-driven world.